Using 68Ga-Pentixafor PET/CT to evaluate thymoma
Chemokine Receptor CXCR4-targeting PET Imaging for Thymoma
This study is testing a new imaging technique to see if it can better identify and understand thymoma in patients who have this rare tumor.
Quick facts
| Phase | Early Phase 1 |
|---|---|
| Study type | Interventional |
| Enrollment | 100 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Peking Union Medical College Hospital Academic / other |
| Locations | 1 site (Beijing, Beijing) |
| Trial ID | NCT06086327 on ClinicalTrials.gov |
What this trial studies
This study investigates the use of 68Ga-Pentixafor PET/CT imaging to assess thymoma, a rare tumor of the thymus gland. It aims to determine if this imaging technique can provide a more accurate metabolic characterization of thymoma compared to traditional methods. The study will include patients with suspected or confirmed untreated thymoma and will evaluate the expression of the CXCR4 receptor, which is linked to tumor progression. The findings could enhance diagnostic capabilities and treatment planning for patients with this condition.
Who should consider this trial
Good fit: Ideal candidates for this study are patients with suspected or confirmed untreated thymoma.
Not a fit: Patients who are pregnant, breastfeeding, or have known allergies to Pentixafor may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved diagnostic accuracy and treatment strategies for patients with thymoma.
How similar studies have performed: While the use of CXCR4-targeting imaging is promising, this specific application in thymoma is novel and has not been extensively tested in prior studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * suspected or confirmed untreated thymoma patients * signed written consent. Exclusion Criteria: * pregnancy * breastfeeding * known allergy against Pentixafor * any medical condition that in the opinion of the investigator,may * significantly interfere with study compliance.
Where this trial is running
Beijing, Beijing
- Peking Union Medical College Hospitall, Chinese Academy of Medical Science and Peking Union Medical College — Beijing, Beijing, China (Recruiting)
Study contacts
- Study coordinator: Rongxi Wang
- Email: zhzwrx.123@163.com
- Phone: +8615584172170
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.